Makoto Nishio

机构：The Cancer Institute Hospital, Japanese Foundation For Cancer Research · ORCID：0000-0003-4969-4165

发表论文 853 篇 · 总被引 32198 次 · h-index 71

代表论文

• Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study (2025 · Journal of Clinical Oncology · 被引 50)
• Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. (2025 · Journal of Clinical Oncology · 被引 43)
• Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial (2025 · Journal of Clinical Oncology · 被引 30)
• Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy (2025 · Journal of Clinical Oncology · 被引 13)
• Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study (2025 · Journal of Thoracic Oncology · 被引 10)
• A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. (2025 · Journal of Clinical Oncology · 被引 2)